•
Sep 30, 2023

biote Q3 2023 Earnings Report

Biote's revenue and Adjusted EBITDA grew, reflecting patient demand for hormone optimization and wellness therapies.

Key Takeaways

Biote reported an 8.5% increase in revenue to $45.6 million and a net income of $19.6 million for the third quarter of 2023. The company's Adjusted EBITDA increased by 14.7% to $14.0 million.

Revenue increased by 8.5% to $45.6 million.

Gross profit margin increased by 70 basis points to 68.9%.

Net income was $19.6 million, with earnings per share of $0.25.

Adjusted EBITDA increased by 14.7% to $14.0 million.

Total Revenue
$45.6M
Previous year: $42M
+8.5%
EPS
$0.24
Previous year: -$1.74
-113.8%
Gross Profit
$31.4M
Previous year: $28.6M
+9.8%
Cash and Equivalents
$85.6M
Free Cash Flow
-$291K
Total Assets
$150M

biote

biote

Forward Guidance

Biote anticipates that 2023 revenue and Adjusted EBITDA will likely be toward the lower end of the provided guidance range.